USA flag logo/image

An Official Website of the United States Government

MOLECULAR BIOMARKERS/NON-INVASIVE DIAGNOSIS OF COLON CA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
59887
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
CA086699
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OXFORD BIOMEDICAL RESEARCH, INC.
2165 AVON INDUSTRIAL DRIVE ROCHESTER HILLS, MI 48309-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: MOLECULAR BIOMARKERS/NON-INVASIVE DIAGNOSIS OF COLON CA
Agency: HHS
Contract: 1R43CA086699-01A2
Award Amount: $96,484.00
 

Abstract:

Colorectal cancer is a leading cause of death in the United States. There is very strong evidence that screening for this disease can reduce colorectal cancer mortality. Present screening methods include fecal occult blood testing (FOBT) and endoscopy, which can detect some early colon cancers and large polyps. However, FOBT screening suffers from large numbers of false positive and negative results. Whereas periodic sigmoidoscopy can significantly reduce mortality from colon cancer, currently only about 7 percent of eligible persons receive sigmoidoscopic screening. The goal of this project is to develop novel non-invasive molecular biomarkers for the diagnosis of human colon cancer based on multiplex PCR amplification of mRNA coding for eicosanoid-metabolizing enzymes in fecal matter, using quantitative PCR methodology. The expression of the target genes will be normalized relative to an epithelial and a leukocyte cell marker, cytokeratine-19 and leukocyte , respectively. In preliminary studies, significant levels of Cox-2 mRNA were found in fecal matter of older in mice, with little or no Cox-2 mRNA in the fecal matter of young Min mice or control wild type mice. Specific aims for Phase I research include: development and optimization of real-time multiplex RT-PCR conditions suitable for isolation and quantification of selected mRNA species in human fecal matter, and preliminary studies on the utility of quantitative multiplex RT-PCR for the diagnosis of human colon cancer using coded fecal samples obtained from normal individuals and from colon cancer patients prior to surgical removal of the colon.

Principal Investigator:

Smiti V. Gupta
2488528815
SGUPTA@OXFORDBIOMED.COM

Business Contact:

Denis Callewaert
2488528815
CALLEWAE@OXFORDBIOMED.COM
Small Business Information at Submission:

OXFORD BIOMEDICAL RESEARCH, INC.
OXFORD BIOMEDICAL RESEARCH, INC. BOX 522, 4600 GARDNER RD METAMORA, MI 48455

EIN/Tax ID: 382506491
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No